AHR and metabolic syndrome: As a blocker of SLC6A14, IDO1 and metabolic syndrome, α-MT can potentially have profound impact on several downstream signaling pathways such as mTOR and AhR because decreased amino acid entry into cells would impair mTOR signaling and decreased generation of kynurenine would suppress AhR signaling.